• Explore /
  • Poster
  • / Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.

Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.

Abstract Poster

Authors

null

Shahneen Kaur Sandhu

Department of Medical Oncology, Peter MacCallum Cancer Centre, Australia, Melbourne, Australia

Shahneen Kaur Sandhu , John A Violet , Justin Ferdinandus , Sue-Ping Thang , Amir Iravani , Christina Guo , Grace Kong , Aravind Ravi Kumar , Timothy J. Akhurst , Alexis Beaulieu , Declan G. Murphy , Jennifer Mooi , Ben Tran , Guy C. Toner , Scott Williams , Rodney J Hicks , Michael Hofman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

12615000912583

Citation

J Clin Oncol 36, 2018 (suppl; abstr 5040)

DOI

10.1200/JCO.2018.36.15_suppl.5040

Abstract #

5040

Poster Bd #

267

Abstract Disclosures

Similar Posters

First Author: Michael Hofman

First Author: Maral DerSarkissian

First Author: Antonin Broyelle

First Author: Andrew Lachlan Schmidt